Cargando…

The Prognostic Index Independently Predicts Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Resection

BACKGROUND: Cancer-related inflammation is associated with tumour proliferation, maintenance and dissemination. It therefore impacts pancreatic cancer survival. The goal of this study was to examine the Prognostic Index (PI) as a prognostic biomarker for survival in patients with pancreatic ductal a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gruber, Elisabeth S., Jomrich, Gerd, Kaider, Alexandra, Gnant, Michael, Sahora, Klaus, Schindl, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Pancreatic Tumors
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210221/ https://www.ncbi.nlm.nih.gov/pubmed/31900809 http://dx.doi.org/10.1245/s10434-019-08161-6

Ejemplares similares

Sarcopenia and sarcopenic obesity are independent adverse prognostic factors in resectable pancreatic ductal adenocarcinoma
por: Gruber, Elisabeth S., et al.
Publicado: (2019)

Correction: Sarcopenia and sarcopenic obesity are independent adverse prognostic factors in resectable pancreatic ductal adenocarcinoma
por: Gruber, Elisabeth S., et al.
Publicado: (2020)

Predictors for Survival in an International Cohort of Patients Undergoing Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma
por: Korrel, M., et al.
Publicado: (2020)

Systemic Immune-Inflammation Index (SII) Predicts Poor Survival in Pancreatic Cancer Patients Undergoing Resection
por: Jomrich, Gerd, et al.
Publicado: (2019)

What Should Guide the Performance of Venous Resection During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma with Venous Contact?
por: Navez, Julie, et al.
Publicado: (2021)

Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (PINC)
por: Redegalli, M., et al.
Publicado: (2022)

Prognostic Impact of Resection Margin Status in Distal Pancreatectomy for Ductal Adenocarcinoma
por: Sahakyan, Mushegh A., et al.
Publicado: (2021)

CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma
por: Maggino, Laura, et al.
Publicado: (2022)

Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study
por: Lof, Sanne, et al.
Publicado: (2019)

Outcomes of Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma in the Netherlands: A Nationwide Retrospective Analysis
por: de Rooij, Thijs, et al.
Publicado: (2015)

Importance of Nodal Metastases Location in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: Results from a Prospective, Lymphadenectomy Protocol
por: Malleo, Giuseppe, et al.
Publicado: (2022)

Development of a Biomarker-Based Scoring System Predicting Early Recurrence of Resectable Pancreatic Duct Adenocarcinoma
por: Ishido, Keinosuke, et al.
Publicado: (2021)

FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analysis and Systematic Review
por: Eshmuminov, Dilmurodjon, et al.
Publicado: (2023)

Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
por: Alva-Ruiz, Roberto, et al.
Publicado: (2021)

Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis
por: Janssen, Quisette P., et al.
Publicado: (2021)

Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity
por: Hill, Colin S., et al.
Publicado: (2022)

Resected Early-Onset Pancreatic Cancer: Practices and Outcomes in an International Dual-Center Study
por: Leonhardt, Carl-Stephan, et al.
Publicado: (2022)

Adjuvant Chemoradiation for Pancreatic Adenocarcinoma: The Johns Hopkins Hospital—Mayo Clinic Collaborative Study
por: Hsu, Charles C., et al.
Publicado: (2010)

Conditional Survival After Resection for Pancreatic Cancer: A Population-Based Study and Prediction Model
por: Latenstein, Anouk E. J., et al.
Publicado: (2020)

Short- and Long-Term Outcomes of Pancreatic Cancer Resection in Elderly Patients: A Nationwide Analysis
por: Henry, Anne Claire, et al.
Publicado: (2022)

Long-term Outcomes After Surgical Resection of Pancreatic Metastases from Renal Clear-Cell Carcinoma
por: Malleo, Giuseppe, et al.
Publicado: (2021)

Preoperative Neutrophil-Lymphocyte and Lymphocyte-Monocyte Ratios Reflect Immune Cell Population Rearrangement in Resectable Pancreatic Cancer
por: Sierzega, Marek, et al.
Publicado: (2016)

Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study
por: van Veldhuisen, Eran, et al.
Publicado: (2022)

Robot-Assisted Versus Laparoscopic Distal Pancreatectomy in Patients with Resectable Pancreatic Cancer: An International, Retrospective, Cohort Study
por: Chen, Jeffrey W., et al.
Publicado: (2023)

Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study
por: Klompmaker, Sjors, et al.
Publicado: (2018)

Impact of Borderline Resectability in Pancreatic Head Cancer on Patient Survival: Biology Matters According to the New International Consensus Criteria
por: Anger, Friedrich, et al.
Publicado: (2020)

A Commentary on “Robot-Assisted Versus Laparoscopic Distal Pancreatectomy in Patients with Resectable Pancreatic Cancer: An International, Retrospective, Cohort Study”
por: Xu, Dingwei, et al.
Publicado: (2023)

Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer
por: Schouten, Thijs J., et al.
Publicado: (2022)

Does Concurrent Cholestasis Alter the Prognostic Value of Preoperatively Elevated CA19-9 Serum Levels in Patients with Pancreatic Head Adenocarcinoma?
por: Anger, Friedrich, et al.
Publicado: (2022)

Nationwide Impact of Centralization, Neoadjuvant Therapy, Minimally Invasive Surgery, and Standardized Pathology Reporting on R0 Resection and Overall Survival in Pancreatoduodenectomy for Pancreatic Cancer
por: Augustinus, Simone, et al.
Publicado: (2023)

Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67
por: Genç, C. G., et al.
Publicado: (2018)

Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver
por: Frigerio, Isabella, et al.
Publicado: (2022)

How to Approach Para-Aortic Lymph Node Metastases During Exploration for Suspected Periampullary Carcinoma: Resection or Bypass?
por: Pranger, Bobby K., et al.
Publicado: (2020)

Surgical Outcome After Pancreatoduodenectomy for Duodenal Adenocarcinoma Compared with Other Periampullary Cancers: A Nationwide Audit Study
por: de Bakker, Jacob K., et al.
Publicado: (2022)

Pathological Margin Clearance and Survival After Pancreaticoduodenectomy in a US and European Pancreatic Center
por: van Roessel, Stijn, et al.
Publicado: (2018)

The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer
por: Perri, Giampaolo, et al.
Publicado: (2020)

Treatment and Survival of Elderly Patients with Stage I–II Pancreatic Cancer: A Report of the EURECCA Pancreas Consortium
por: Groen, Jesse V., et al.
Publicado: (2020)

Induction Chemotherapy with FOLFIRINOX for Locally Advanced Pancreatic Cancer: A Simple Scoring System to Predict Effect and Prognosis
por: Tanaka, Masayuki, et al.
Publicado: (2022)

Intraoperative Ultrasound During Surgical Exploration in Patients with Pancreatic Cancer and Vascular Involvement (ULTRAPANC): A Prospective Multicenter Study
por: Michiels, Nynke, et al.
Publicado: (2023)

Long-Term Outcomes of Tuberous Sclerosis Complex-Associated Non-functional Pancreatic Neuroendocrine Tumors: Should We Be More Conservative?
por: Arya, Shahrzad, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c6uahhiimhc8ps7pisnqpmp0tl